Navigation Links
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Date:4/25/2012

HAYWARD, Calif., April 25, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the completion of dosing in the Company's Phase 2b PEARL-SC study. PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of monthly and weekly subcutaneous administration of blisibimod in systemic lupus erythematosus (SLE) patients.

The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index  (SRI)-- a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI* improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

In addition to the primary endpoint analysis, PEARL-SC will provide a series of key secondary subgroup and endpoint analyses which will help guide the design of phase 3 registration studies and further differentiate blisibimod from currently available therapies.  These prospective secondary and exploratory analyses include:

  • Larger improvement in disease activity, as measured by SELENA/SLEDAI reductions of 5, 6, 7 and 8;
  • The percentage of patients achieving the primary endpoint and requiring no increase in steroid dose from baseline;
  • Percentage of patients able to reduce steroid dose and percentage of patients requiring no increase in steroid dose;
  • Time to first SLE flare and first severe SLE flare;
  • Disease activity improvement in lupus patients
    '/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... July 4, 2015 ... eerstelijns chemotherapie voor patiënten met niet-resectabele uitgezaaide ... de progressievrije overleving in dat orgaan. ... kanker (mCRC) die alleen binnen de lever ... progressievrije overleving (PFS) in de lever dankzij ...
(Date:7/3/2015)... According to a new ... Management Market ECG, Implantable Loop Recorder, Manual Event ... Dual Chamber Pacemaker, CRT-D, CRT-P - Global Forecast ... Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices ... 2020 from $21,137.7 Million in 2015, at a ...
(Date:7/3/2015)... NEW YORK , July 3, 2015  Obsidian ... ) - an online service for the management of ... professionals announced today that PharmaShine now includes the 2014 ... Center for Medicare Services on June 30. The data ... 11.4 million transactions between industry and providers totaling $6.49 ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Pittsburgh -based Foundation Radiology Group (FRG), a premier provider ... strategic partnership with Acusis, a national provider of outsourced medical transcription ... , , ... Acusis delivers healthcare solutions that are designed to improve the productivity ...
... SHENZHEN, China , July 20 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International ... of medical devices worldwide, today announced that it will report its,financial ... after the U.S.,market closes on August 9, 2010 . Mindray,s ... on August 10, 2010 U.S. Eastern Time ( 8:00 ...
Cached Medicine Technology:Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 2Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 3Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010 2Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010 3
(Date:7/6/2015)... , ... July 06, 2015 , ... The Path of ... into the economic transformation associated with the U.S. economy over the past 40 years. ... with its use. In many ways, the book is a time capsule that chronicles ...
(Date:7/5/2015)... ... July 05, 2015 , ... World Patent Marketing, a vertically ... invention that effectively removes weeds without harming man and nature. , "The ... and Creative Director of World Patent Marketing. "It is projected to grow at ...
(Date:7/4/2015)... Florida (PRWEB) , ... July 04, 2015 , ... ... of Plastic Surgeons published the results of an annual member survey , ... the United States. More recently, the group broke that raw data down into ...
(Date:7/3/2015)... ... July 04, 2015 , ... The Harvest Hope Food Bank will hopefully be getting ... AlignLife offices in the area of Greenville SC are making it their mission to ... patients only. They are asking for donations from the public as well. As part of ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
Breaking Medicine News(10 mins):Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2
... a subsidiary of MGT Capital Investments, Inc. (NYSE-A: ... of Computer-Aided Detection (CAD) and image analysis software, ... disease, today announces the following restructuring of its ... currently Chief Financial Officer, becomes Chief Executive Officer; ...
... Bill Would Create National Patient Registry, Increase Public ... The Coalition for Pulmonary Fibrosis (CPF) is excited ... pulmonary fibrosis (PF) advocacy program -- the introduction ... 2009 (PFREA) in the 111th Congress. The PFREA, ...
... beneath the ocean,s surface, tiny phytoplankton swimming upward in ... watery equivalent of Rod Serling,s Twilight Zone: a sharp ... single-celled organisms and sends them tumbling until a shift ... them free. , Scientists are aware of these ...
... Crestline Custom Imprinted Products, a direct marketing promotional products company, ... items. , ... Lewiston, ME (PRWEB) ... marketing promotional products company that trades on its ...
... a Use Not Approved By the Food and Drug ... in two whistleblower suits filed in the Northern District ... its parent company, Johnson & Johnson Inc., alleging that ... use not approved by the Food and Drug Administration ...
... a 40% Reduction of Intraocular Pressure at Two Years ... that it has surpassed 1000 implantation procedures with its ... intraocular pressure (IOP) for the treatment of glaucoma. ... and Founder of SOLX, "as it validates the importance ...
Cached Medicine News:Health News:Medicsight PLC Restructures Management Team 2Health News:Medicsight PLC Restructures Management Team 3Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 2Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 3Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 4Health News:MIT research could help predict red tide 2Health News:MIT research could help predict red tide 3Health News:Crestline is the Source for Great Green Giveaways 2Health News:Crestline is the Source for Great Green Giveaways 3Health News:United States Joins Suits Against Scios and Johnson & Johnson 2Health News:United States Joins Suits Against Scios and Johnson & Johnson 3Health News:SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment 2
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: